Antibody discovery research paves the way for new therapeutics. The search for the right antibody for a specific therapeutic application necessitates several iterations of antibody production and ...

Collaboration leverages Converge Bio's proprietary generative AI to design and optimize novel tri-specific antibodies for oncology needsAI-driven ...

Developers often treat payload selection, conjugation chemistry and commercial scale-up as isolated operations. This ...

Antibody-drug conjugates (ADCs) are transforming oncology by combining the precision of monoclonal antibodies with the potency of cytotoxic drugs. Yet, developing effective ADCs requires overcoming ...

A lack of targeting specificity has been a long-running problem for cytotoxic anticancer agents, with excess side effects limiting their effectiveness. Scientists have turned to antibodies, and their ...

Archon Bioscience s, a biotech startup putting AI to work designing novel biomolecules, has just emerged from stealth with an impressive $20 million in seed funding. The company aims to supercharge ...

Adagene Inc. has announced a partnership with ConjugateBio Inc. to provide a proprietary antibody for the development of innovative bispecific antibody-drug conjugates (ADCs). Adagene's CEO ...

Antibody-drug conjugates (ADCs) have revolutionized the oncology field, offering targeted cancer treatments that improve efficacy without adversely affecting healthy cells. 1 ADCs’ potential extends ...

The "Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering. Antibody drug conjugates ...

DURHAM, N.C.--(BUSINESS WIRE)--KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), announces a manufacturing contract ...